Mohamed AA

No ORCID on file · 3 papers in corpus · active 2022-2025

Study types

  • meta-analysis 1

Condition tags

  • dysmenorrhea 1
  • chronic_pelvic_pain 1
  • adenomyosis 1
2025
FDA approves Veozah (Fezolinetant) for menopausal symptoms: a new nonhormonal option.
Annals of medicine and surgery (2012) ·doi:10.1097/ms9.0000000000003670

Menopausal vasomotor symptoms (VMS), such as hot flashes and night sweats, significantly impact the quality of life for many women. While hormone therapy remains a standard treatment, it is not suitable for all patients due to contraindicat…

meta-analysis 2024
The use of dienogest in treatment of symptomatic adenomyosis: A systematic review and meta-analysis
Journal of gynecology obstetrics and human reproduction ·doi:10.1016/j.jogoh.2024.102795

Adenomyosis is a gynaecological problem that impacts women's quality of life by causing dysmenorrhea, chronic pelvic pain, and menorrhagia. The search continues for the best medical treatment for symptomatic adenomyosis. This systematic rev…

2022
The Impact of High Circulating Anti-Müllerian Hormone on Endometrial Thickness and Outcome of Assisted Reproductive Technology in Women with Polycystic Ovarian Syndrome: A Cohort Study.
Journal of human reproductive sciences ·doi:10.4103/jhrs.jhrs_112_22

BackgroundElevated circulating anti-Müllerian hormone (AMH) in women with the polycystic ovarian syndrome (PCOS) has been found to have a detrimental effect on endometrial function. This may adversely affect the outcome of in vitro fertilis…